Platelet dysfunction and end-stage renal disease

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 317-322

  Kaw, Dinkar ^a,b   Malhotra, Deepak ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Ruppert Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING DISORDER; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; THROMBOCYTE; THROMBOCYTE DISORDER;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HEMORRHAGIC DISORDERS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 33746255918     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00179.x     Document Type: Review

References (86)

1. Morgagni GB: Opera Omnia Ex Typographia Remondiniana. Venezia, Italy, 1764
2. Bright R: Tabular view of morbid appearance in 100 cases connected with albuminous urine: with observations. Guy's Hosp Rep 1:380-400, 1836
3. Di Minno G, Maitinez J, McKean ML, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. Am J Med 79:552-559, 1985
4. Bloom AI, Evans EP, Branch RA: Platelet function in chronic renal failure. Acta Univ Carol Med Monogr 53:333-338, 1972
5. Evans EP, Branch RA, Bloom AI: A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 25:745-753, 1972
6. Lewis JH, Zucker MB, Ferguson JH: Bleeding tendency in uremia. Blood 11:1073-1076, 1956
7. Rath CE, Mailliard JA, Schreiner GE: Bleeding tendency in uremia. N Engl J Med 257:808-811, 1957
8. Berger HW, Rammohan G, Neff MS, Buhain WJ: Uremic pleural effusion: a study in 14 patients on chronic dialysis. Ann Intern Med 82:362-364, 1975
9. Symmons HS, Wrong OM: Uremic pericarditis with cardiac tamponade: a report of four cases. Br Med J 1:605-606, 1964
10. Alfrey AC, Goss JE, Ogden DA, Vogel JH, Holmes JH: Uremic hemopericardium. Am J Med 45:391-400, 1968
11. Schafer AI: Acquired disorders of platelet function. In: Loscalzo J, Schafer AI (eds), Thrombosis and Hemorrhage. Oxford: Blackwell Scientific, 1994:635-653
12. Jurk K, Kehrel BE: Platelet. Physiol Biochem Semin Thromb Hemost 4:381-392, 2005
13. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin Thromh Hemost 5:579-589, 2004
14. Escolar G, Diaz-Ricart M, Cases A: Uremic platelet dysfunction: past and present. Curr Hematol Rep 4:359-367, 2005
15. Weigert AL, Schafer AI: Uremic bleeding: pathogenesis and therapy. Am J Med Sci 316:94-104, 1998
16. Di Minno G, Cerbone A, Usberti M: Platelet dysfunction in uremia II. Correction by arachidonic acid of impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108:246-252, 1986
17. Luscher EF, Weber A: The formation of the haemostatic plug - a special case of platelet aggregation. An experiment and a survey of literature. Thromb Haemost 70:234-237, 1993
18. Smith MC, Dunn M: Impaired thromboxane produced in renal failure. Nephron 29:133-137, 1981
19. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G: Reduced thromboxane formation in uremia: evidence for functional cyclooxygenase defect. J Clin Invest 71:762-768, 1983
20. Macconi D, Vigano G, Bisogno G, Galbusera M, Orisio S, Remuzzi G: Defective platelet aggregation in response to platelet activation factor in uremia associated with low platelet thromboxane A2 generation. Am J Kidney Dis 19:318-325, 1992
21. Castillo R, Lozano T, Escolar G: Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 68:337-342, 1986
22. Larsson SO: On coagulation and fibrinolysis in renal failure. Scan J Haematol Suppl 15:1-59, 1971
23. Mezzano D, Tagle R, Panes O: Hemostatic disorder of uremia: the platelet defect, main determinant of prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 76:312-321, 1996
24. Bazilinski N, Shaykh M, Dunea G: Inhibition of platelet function by uremic middle molecules. Nephron 40:423-428, 1985
25. Escolar G, Diaz-Ricart M, Cases A: Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol 143:823-831, 1991
26. Ordinas A, Escolar G, White JG: Ultrastructure of platelets and platelet-surface interaction. In: Missirlis YF, Wautier JL (eds), The Role of Platelets in Blood-Biomaterial Interactions. Amsterdam: Kluwer Academic, 1993:3-13
27. Hakim RM, Schafer AI: Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 78:575-580, 1985
28. Knudsen F, Nielsen AH, Kristensen SD: The effect of dialyser membrane material on intradialytic changes in platelet count, platelet aggregation, circulating platelet aggregates and antithrombin III. Scand J Urol Nephrol 19:227-232, 1985
29. Clemetson KJ, Clemetson JM: Platelet GPIb-V-IX complex. Structure, function, physiology and pathology. Semin Thromb Hemost 21:130-136, 1995
30. Benigni A, Boccardo P, Galbusera M: Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 22:668-676, 1993
31. Escolar G, Monteagudo J, Castillo R: Ultrastructural immunolocalization and morphometric quantification of platelet membrane GP Ib and GP IIb-IIIa in uremic patients. Prog Clin Biol Res 283:197-201, 1988
32. Sloand EM, Sloand JA, Prodouz K: Reduction of platelet glycoprotein Ib in uremia. Br J Haematol 77:375-381, 1991
33. Gawaz MP, Dobos G, Spath M: Impaired function of platelet membrane glycoprotein IIa-IIIb in end-stage renal disease. J Am Soc Nephrol 5:36-46, 1994
34. Sreedhara R, Itagaki I, Hakim RM: Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIa-IIIb receptors. Am J Kidney Dis 27:355-364, 1996
35. Moncada S, Herman AG, Higgs EA, Vane JR: Differential formation of prostacyclin (PGI2) by layers of arterial wall: an explanation for the antithrombotic properties of vascular endothelium. Thromb Res 11:323-344, 1977
36. Remuzzi G, Cavernaghi AE, Mecca G, Donati MB, de Gaetano G: Prostacyclin like activity and bleeding in renal failure. Lancet 2:1195-1197, 1977
37. Viachoyannia J, Schoeppe W: Adenylyl cyclase activity and cyclic AMP content of human platelets in uremia. Eur J Clin Invest 12:379-381, 1982
38. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414-416, 1986
39. Radomski MW, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87:5193-5197, 1990
40. Marietta M, Facchinetti F, Neri I: L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 88:229-235, 1997
41. Noris M, Benigni A, Boccardo P: Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 44:445-450, 1993
42. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E: Parathyroid hormone inhibits human platelet function. Lancet 2:1321-1323, 1981
43. Benigni A, Livio M, Dodesini P, Schieppati A, Panigada M, Mecca G, de Gaetano G, Remuzzi G: Inhibition of human platelet aggregation by parathyroid hormone: is cyclic AMP implicated? Am J Nephrol 5:243-247, 1985
44. Docci D, Turci F, Delvecchio C, Gollini C, Baldrati L, Pistocchi E: Lack of evidence for the role of secondary hyperparathyroidism in the pathogenesis of uremic thrombocytopathy. Nephron 43:28-32, 1986
45. Fernandez F, Goudable C, Sie P: Low hematocrit and prolonged bleeding time in uremic patients: effect of red cell transfusions. Br J Haematol 59:139-148, 1985
46. Howard AD, Moore J Jr, Welch PG, Gouge SF: Analysis of the quantitative relationship between anemia and chronic renal failure. Am J Med Sci 297:309-313, 1989
47. Turitto VT, Weiss HJ: Red blood cells: their dual role in thrombus formation. Science 207:541-543, 1980
48. Gaarder A, Jonsen J, Lland S: Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531-532, 1961
49. Willems C, Stel HV, van Aken WG, Van Novrik JA: Binding and inactivation of prostacycline (PGI2) by human erythrocytes. Br J Haematol 54:43-52, 1983
50. Moia M, Mannucci PM, Vizzotto L: Improvement in the haemostatic defect of uremia after treatment with recombinant human erythropoietin. Lancet 2:1227-1229, 1987
51. Vigano G, Benigni A, Mendogni D: Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 18:44-49, 1991
52. Diaz-Ricart M, Etebanell E, Cases A, Lopez-Pedret J, Castillo R, Ordinas A, Escolar G: Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 82:1312-1317, 1999
53. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R: Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 42:668-672, 1992
54. Rabiner SF, Molinas F: The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 49:346-351, 1970
55. Horowitz HI, Stein IM, Cohen BD, White JG: Further studies on platelet inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 49:336-345, 1970
56. Remuzzi G, Livio E, Marchiaro G, Mecca G, de Gaetano G: Bleeding in renal failure: altered platelet function in chronic uremia only partially corrected by haemodialysis. Nephron 22:347-353, 1978
57. Remuzzi G, Marchesi D, Livio M: Altered platelet and vascular prostaglandin generation in patients with renal failure and prolonged bleeding times. Thromb Res 13:1007-1015, 1978
58. Sloand JA, Sloand EM: Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 8:799-803, 1997
59. Aggarwal A, Kabbani SS, Rimmer JM, Gennari FJ, Taatjes DJ, Sobel BE, Schneider DJ: Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 40:315-322, 2002
60. Mathur SC, Miller JL, Narsipur SS: Effect of hemodialysis on hemostatic platelet function in uremic patients. J Am Soc Nephrol 11:286A, 2000
61. Lindsay RM, Friesen M, Koens F, Linton AL, Oreopoulos D, de Vaber G: Platelet function in patients on long-term peritoneal dialysis. Clin Nephrol 6:335-339, 1976
62. Salvati F, Liani M: Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 24:131-135, 2001
63. Sloand EM, Bern MM, Kaldany A: Effect on platelet function of hypoalbuminemia in peritoneal dialysis. Thromb Res 44:419-425, 1986
64. Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ: Platelet-mediated bleeding caused by broad spectrum penicillins. J Infect Dis 155:1242-1248, 1987
65. Andrassy K, Ritz E: Uremia as a cause of bleeding. Am J Nephrol 5:313-319, 1985
66. Bang N, Tessler S, Heidenreich R, Marks C: Effects of moxolactam on blood coagulation and platelet function. Rev Infect Dis 4:S546-S554, 1982
67. Simon SL, Mills JA: Non-steroidal anti-inflammatory drugs. N Engl J Med 302:1237-1343, 1980
68. Harker LA, Fuster V: Pharmacology of platelet inhibitors. J Am Coll Cardiol 8:21B-32B, 1986
69. Casserly LF, Dember LM: Thrombosis in end-stage renal disease. Semin Dial 16:245-256, 2003
70. Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, Ordinas A: Platelet activation on hemodialysis: influence of dialysis membranes. Kidney Int 43(suppl 41):217-220, 1993
71. Gawaz MP, Mujais SK, Schmidt B, Gurland HJ: Platelet-leukocyte aggregation during hemodialysis. Kidney Int 46:495, 1994
72. Sirolli V, Strizzi L, Di Stante S, Robuffo I, Procopio A, Bonomini M: Platelet activation and platelet erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost 86:834-839, 2001
73. 2+ response. Blood 90:2615-2625, 1997
74. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V: Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2:1275-1281, 2004
75. Miyazaki Y, Nomura S, Miyake T: High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 88:3456-3464, 1996
76. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H: Circulating platelet derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 62:1757-1763, 2002
77. Lindsay RM, Friesen M, Aronstam A: Improvement of platelet function by increased frequency of hemodialysis. Clin Nephrol 10:67-70, 1978
78. Kim YG: Anticoagulation during haemodialysis in patients at high risk of bleeding. Nephrology 8:S23-S27, 2003
79. Lohr JW, Schwab SJ: Minimizing haemorrhagic complications in dialysis patients. J Am Soc Nephrol 2:961-975, 1991
80. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D: Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318-1322, 1980
81. Zeigler ZR, Megaludis A, Fraley DS: Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 39:90-95, 1992
82. Mannucci PM, Remuzzi G, Pusineri F: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8-12, 1983
83. Heistinger M, Stockenhuber F, Schneider B: Effect of conjugated estrogen on platelet function and prostacyclin generation in CRF. Kidney Int 38:1181-1186, 1990
84. Remuzzi G, Perico N, Zoja C: Role of endothelium derived nitric oxide in bleeding tendency of uremia. J Clin Invest 86:1768-1771, 1990
85. Sloand JA, Schiff MJ: Beneficial effect of low dose transdermal estrogen on bleeding tome and clinical bleeding in uremia. Am J Kidney Dis 26:22-26, 1995
86. Livio M, Gotti E, Marchesi D: Uraemic bleeding. Role of anemia and beneficial effect of red cell transfusion. Lancet 2:1013-1015, 1982